For the latest salvo in the global battle for cardiac stent supremacy, we turn to Japan and St. Jude Medical. The Minnesota device company sees the country's enormous cardiac device and medical device market as ripe for its next-generation imaging system for stent placement, and the launch is now under way.
Japan's conglomerate Ajinomoto is giving its pharmaceutical operations a double boost of investment. The company is expanding an ingredient plant in China while joining a host of other companies expanding in biologics manufacturing.
Prowling the world's markets for new buyouts, Japan's Ajinomoto has pounced on San Diego-based Althea Technologies, striking a deal to buy the biopharmaceutical development and manufacturing outfit for about $175 million.
Capsule maker Qualicaps is moving ahead with an expansion at its plant in North Carolina even as a new owner takes control of the company.
Boston Scientific is looking to expand its share of the Japanese neuromodulation market, signing on with a local devicemaker to sell its Precision Plus spinal cord system in the country.
Takeda Pharmaceutical and one of its contract manufacturers have run afoul of authorities in Japan, leading to the temporary closure of a manufacturing plant.
Japan's Eisai is unloading a nearly four-decade-old plant in Taiwan as it remakes its manufacturing network.
Japan's regulators may speed up the approval process for some generic medical devices, a big development in one of the world's largest markets for healthcare products and services.
Switzerland's Biosensors International will work with Japan's Terumo to promote that company's Nobori drug-eluting stent in Japan.
Japan-based NanoCarrier and Taiwan's Orient Europharma are expanding their rare collaboration by jointly building a new manufacturing plant in the Republic of China.